Psychedelic: Relmada acquires neurosteroid from Asarina
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on an acquisition, study results ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
psychiatryadvisor.com1d
Cariprazine Demonstrates Efficacy Across Age Groups in Bipolar I Disorder
In a post-hoc analysis, cariprazine seemed to be effective in treating both depressive and manic episodes of bipolar I disorder across age groups.
H.C. Wainwright maintains buy on GH Research stock, $40 target
GH Research PLC (NASDAQ:GHRS) received a reiterated Buy rating and $40.00 price target from H.C. Wainwright, representing significant upside potential for the $936 million market cap company. The ...
BioSpace3d
GH’s Inhaled Psychedelic Succeeds in Mid-Stage Depression Trial
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
GH Research reports breakthrough in depression treatment
DUBLIN - GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company valued at $551.5 million, announced today significant results from its Phase 2b clinical trial for GH001, an ...
FierceBiotech3d
Irish biotech's inhaled drug reduces depression in phase 2 trial
The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...